SOURCE: Bio-Rad Laboratories

May 17, 2011 08:30 ET

Bio-Rad Launches Antiphospholipid Syndrome IgG, IgM, and IgA Kits for Its BioPlex 2200 System

Novel Automated Multiplexing Technology Streamlines Antiphospholipid Antibody Testing and Optimizes Laboratory Efficiency

HERCULES, CA--(Marketwire - May 17, 2011) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the European and Canadian launch of its BioPlex® 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits for use on its BioPlex® 2200 system. Antiphospholipid Syndrome is an autoimmune disease in which the body's immune system mistakenly produces antibodies to certain blood proteins causing thrombosis (clotting) within arteries, veins, and small blood vessels.

Patients with Antiphospholipid Syndrome are at risk of strokes and heart attacks. In addition, thrombosis within arteries and veins has the potential to affect other organs such as the lungs, liver, and kidney.

The BioPlex 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits are used as an aid in the diagnosis of this disease by simultaneously detecting two autoantibodies (anti-Cardiolipin and anti-Beta-2 Glycoprotein I) and therefore leading to faster and better care for those suffering from this syndrome.

"The release of the Antiphospholipid Syndrome reflects our continued commitment to expand our menu around the BioPlex 2200 testing system," said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. "By obtaining multiplex results from a single patient sample, laboratories and physicians can get the answers they need to provide faster and more effective patient treatment."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests, which are traditionally processed separately, using a single small volume patient sample.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,800 people globally and had revenues exceeding $1.9 billion in 2010. For more information, visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Contact Information

  • For more information, please contact:
    Bio-Rad Laboratories, Inc.
    Tina Cuccia
    Corporate Communications
    Email Contact